News
We send the latest information from SMC Laboratories.
NIDDK's publication in Purinergic Signaling
SMC announces that NIDDK (MD) has published the results of a study using the STAMTM mouse model in Purinergic Signaling. Title: “Design and in vivo activity of A3 adenosine receptor agonist prodrugs” https://link.springer.com/article/10.1007/s11302-020-09715-0 In this paper, they report the results of a pharmacology study of a A3 adenosine receptor agonist prodrug (MRS7476) using…
Genfit announced that it will discontinue the Phase 3 NASH study and concentrate on the developmento of PBC therapeutics.
Genfit (France) announced on July 22, 2020, that it will discontinue Elafibranor's Phase 3 NASH clinical trial and concentrate on developing PBC therapeutics. RESOLVE-IT Phase 3 clinical trial did not show any improvement in the primary endpoint, resulting in a change in corporate strategy. Following the recent news of OCA, the drop of Elafibranor,…
DURECT has published a news release regarding positive topline data from phase 1b study of DUR-928 in NASH
DURECT CORPORATION (USA) announced on May 26, 2020, that positive topline data was obtained in serum liver enzymes (ALT, AST, GGT) and liver stiffness as measured by Fibroscan in the Phase 1b for NASH patients. DUR-928 is a endogenous epigenetic regulator. The compound used the STAMTM mouse model for non-clinical studies, and data showing…
FDA rejects Intercept Pharma's drug for NASH for now
Intercept Pharmaceuticals, Inc. (USA) announced that it has received a notification from the FDA that it will not approve the application for FXAR agonist (OCA) for liver fibrosis by NASH on June 29, 2020. OCA has reported to have side efects such as itching and an increase in total cholesterol level. The announce is…
Hepion pharma has publshed a pres releaes regarding the CRV431 efficacy evaluation study for kidney fibrosis we have provied.
Hepion pharma, which is our client, has announced the results of pharmacology study using a UUO mouse model. CRV431 is a cyclophillin inhibitor. In addition to the UUO mouse model, this compound exerts its anti-fibrosis effects in other fibrosis models such as the STAMTM mouse model, and is expected for future clinical development. …
Enzychem Lifesciences Corporation’s presentation at AASLD The Liver Meeting® 2019 in Boston.
SMC announced that Enzychem Lifesciences Corporation presented results of a study using STAM™ model at poster presentation at AASLD The Liver Meeting® 2019 in Boston, MA, November 8-12, 2019. Title: “EC-18, a novel immune resolution accelerator, improves NASH and liver fibrosis”
Enyo Pharma SA’s presentation at AASLD The Liver Meeting® 2019 in Boston.
SMC announced that Enyo Pharma SA presented results of a study using STAM™ model at poster presentation at AASLD The Liver Meeting® 2019 in Boston, MA, November 8-12, 2019. Title: “In vitro and in vivo characterization of EYP001 a novel, potent and selective FXR agonist now in a phase 2 clinical trial in NASH”
Dr. Falk Pharma GmbH’s presentation at AASLD The Liver Meeting® 2019 in Boston.
SMC announced that Dr. Falk Pharma GmbH presented results of a study using STAM™ model at poster presentation at AASLD The Liver Meeting® 2019 in Boston, MA, November 8-12, 2019. Title: “Norursodeoxycholic acid (norUDCA) significantly ameliorates liver injury in the STAM mouse model for non-alcoholic steatohepatitis (NASH)”
NeuroVive Pharmaceutical’s publication on Cells.
SMC announced that NeuroVive Pharmaceutical has published the results of a study using STAM™ model on International Journal of Molecular Sciences. Title: “Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis”
Dokkyo Medical University’s publication on International Journal of Molecular Sciences.
SMC announced that Dokkyo Medical University has published the results of a study using STAM™ model on International Journal of Molecular Sciences. Title: “The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma”